Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Isoferulic acid is a naturally occurring phenolic compound classified as a hydroxycinnamic acid derivative. It is found as a major active ingredient in the rhizome of Cimicifuga heracleifolia and other plants. Isoferulic acid exhibits multiple biological activities, including anti-inflammatory, antioxidant, antiviral, antidiabetic, and anticancer effects[1][4][6]. Mechanistically, it has been shown to inhibit capsule synthesis in Klebsiella pneumoniae by reducing capsular polysaccharide production[4], induce G2/M-phase cell cycle arrest and apoptosis in leukemia cells via inhibition of Akt/mTOR signaling[6], and activate adrenergic receptors[1]. Its broad pharmacological profile makes it an experimental candidate for various therapeutic applications.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Isoferulic acid.